Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7.

Akache, Bassel; Weeratna, Risini D; Deora, Aparna; Thorn, Jennifer M; Champion, Brian; Merson, James R; Davis, Heather L; McCluskie, Michael J.

Afiliação

Akache B; Pfizer Vaccine Immunotherapeutics, Ottawa Laboratories, 340 Terry Fox Drive, suite 200, Ottawa, ON K2K 3A2, Canada. bassel.akache@pfizer.com.
Weeratna RD; Pfizer Vaccine Immunotherapeutics, Ottawa Laboratories, 340 Terry Fox Drive, suite 200, Ottawa, ON K2K 3A2, Canada. risini.weeratna@pfizer.com.
Deora A; Pfizer Biotherapeutics Pharmaceutical Sciences, St. Louis, MO 63017, USA. aparna.deora@pfizer.com.
Thorn JM; Pfizer Biotherapeutics Pharmaceutical Sciences, St. Louis, MO 63017, USA. jennifer.thorn@pfizer.com.
Champion B; Pfizer Vaccine Immunotherapeutics, La Jolla, CA 92121, USA. brian.champion@psioxus.com.
Merson JR; Pfizer Vaccine Immunotherapeutics, La Jolla, CA 92121, USA. james.merson@pfizer.com.
Davis HL; Pfizer Vaccine Immunotherapeutics, Ottawa Laboratories, 340 Terry Fox Drive, suite 200, Ottawa, ON K2K 3A2, Canada. heather.davis@pfizer.com.
McCluskie MJ; Pfizer Vaccine Immunotherapeutics, Ottawa Laboratories, 340 Terry Fox Drive, suite 200, Ottawa, ON K2K 3A2, Canada. michael.mccluskie@pfizer.com.

Vaccines (Basel) ; 4(1)2016 Jan 21.

Article em En | MEDLINE | ID: mdl-26805897